Lyon Sarcoid Uveitis Cohort

Sarcoid Uveitis Clinical Trial

— LUCS  

Official title:

Lyon Sarcoid Uveitis Cohort

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03863782
• Other study ID #: CRC_GHN_2018_001
• Status: Recruiting
• Start date: January 1, 2016
• Est. completion date: January 1, 2025

Study information

• Verified date: April 2024
• Source: Hospices Civils de Lyon
• Contact: Pascal SEVE
• Email: pascal.seve[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Sarcoidosis is a systemic disease with unknown etiology. Chronicity of the disease is observed in 1/3 of cases. Five percent of the affected patients are expected to die due to pulmonary worsening. After pulmonary complications, ocular complications are one of the most frequent complications. In hospital setting 2 to 15% of patients who come for initial uveitis diagnosis are after examination due to Sarcoidosis. Sarcoidosis diagnosis is based on paraclinical exams (biological, radiography) and histological confirmation. Corticotherapy (local or general) is usually used to cure sarcoid uveitis. In case of failure immunosuppressor or anti-tumor necrosis factor (TNF) can be used. In 10% of cases ocular symptoms including blindness are observed. Only treatment administrated quickly after diagnosis of sarcoid uveitis can prevent from ophthalmologic complications.

The main objective of the Lyon Sarcoid Uveitis Cohort study is to analyze the relevance of the paraclinical exam for sarcoid uveitis diagnosis, and to define a better visual and extra-ophthalmologic prognosis and describe the therapeutic practice in our Department.

This study is proposed to all patients diagnosed with Sarcoid uveitis with a histological confirmation and referred to the internal medicine department of the Croix-Rousse hospital, Lyon, France, for etiologic diagnosis or treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: January 1, 2025
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of sarcoid uveitis

• First consultation in the department of Internal Medicine at the Croix-Rousse hospital, Lyon, France

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Sarcoid Uveitis
• Sarcoidosis
• Uveitis

Intervention

Other:
• No intervention
No specific intervention. Collection of clinical data

Locations

Country	Name	City	State
France	Hospices Civils de Lyon	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical evolution (persistence or resolution) evaluated by gradation of SEN	Persistence of disease is characterized by persistence of intraocular inflammation evaluated by gradation of SEN. (reference: A Standardization Grading System for Scleritis . Ophthalmology 2011 Apr;118(4):768-71). SEN score ranges from 0 to 5 (resolution = score 0 and persistence = score >0)	At one year after diagnosis
Secondary	Anatomic characteristic of sarcoid uveitis	The anatomic characteristics of sarcoid uveitis will be described: anterior or posterior inflammation of greater rings of iris, ciliary margin of iris	At inclusion visit
Secondary	Corticoid treatment duration	Treatment used to cure uveitis: duration of corticotherapy treatment	At one year after diagnosis